Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-05-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
自愿披露关于创新药GB18注射液获得美国FDA新药临床试验许可的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about receiving FDA approval for clinical trial application of an innovative drug GB18 injection. It includes details about the drug, regulatory approval, and impact on the company. The document is short (1485 characters) and serves as an announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual report, interim report, earnings release, or any other detailed financial or governance report. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-05-21 Chinese
关于以集中竞价交易方式回购股份比例达到总股本1%暨股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program, including details on the number of shares repurchased, the price range, and the percentage of total share capital repurchased. It references regulatory compliance with stock exchange rules and previous announcements about the share buyback plan. The document does not contain financial statements or detailed financial analysis but focuses on the update of the share repurchase activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2025-05-13 Chinese
关于参加2025年山东辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its participation in an investor online collective reception day event. It mentions the date and time of the event and topics to be discussed, such as 2024 annual and 2025 Q1 performance, governance, strategy, and shareholder incentives. The document does not contain actual financial statements or detailed financial data, nor is it a transcript or report. It is a notice about an upcoming investor interaction event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-05-12 Chinese
北京市嘉源律师事务所关于科兴生物制药股份有限公司2024年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of the 2024 Annual General Meeting (AGM) of 科兴生物制药股份有限公司. It details the legal compliance of the AGM process, including the notice, voting methods, and resolutions passed. The document does not contain the actual annual report or financial statements but rather provides a legal opinion on the AGM proceedings and voting results. The document length is 3287 characters, which is relatively short and consistent with a legal opinion or meeting-related announcement rather than a full report. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the official results and legality of the shareholder votes at the AGM.
2025-05-08 Chinese
2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 Annual General Meeting (AGM) of 科兴生物制药股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, board and supervisory reports, financial statements, profit distribution, remuneration standards, and share issuance authorization. The document also contains legal witness statements confirming the validity of the meeting and voting process. The content is focused on the voting results and meeting proceedings rather than the full annual report or financial statements themselves. The document length is 3141 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, the document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-08 Chinese
关于调整回购股份价格上限的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company regarding the adjustment of the upper limit price for its share repurchase program. It details the board's decision to increase the maximum repurchase price, the rationale behind the adjustment, and confirms that the other terms of the repurchase plan remain unchanged. The document also states that this adjustment does not require shareholder approval and includes risk disclosures related to the repurchase. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The content clearly fits the category of a company announcement about its share repurchase activity, which corresponds to the 'Transaction in Own Shares' category (POS). The document length is short and focused solely on this update, confirming it is not a full report or a regulatory filing of another type.
2025-05-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.